Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737668 | 0.91 | S1PR1 (0.45) | S1PR1S1PR5P2RY12NPC1ALDH1A1 | |
| SCHEMBL6115727 | 0.85 | P2RY12 (0.45) | P2RY12LMNA | |
| SCHEMBL6117360 | 0.82 | P2RY12 (0.43) | P2RY12LMNA | |
| SCHEMBL6116806 | 0.80 | P2RY12 (0.47) | P2RY12LMNA | |
| SCHEMBL6116507 | 0.80 | NPSR1 (0.57) | S1PR1S1PR5LMNA | |
| SCHEMBL6116492 | 0.77 | MEN1 (0.48) | ALDH1A1TP53LMNA | |
| SCHEMBL6117731 | 0.76 | S1PR1 (0.54) | S1PR1S1PR5 | |
| SCHEMBL8738244 | 0.74 | POLB (0.47) | ALDH1A1TP53LMNA | |
| SCHEMBL8737669 | 0.72 | P2RY12 (0.41) | P2RY12LMNA | |
| SCHEMBL13215741 | 0.69 | S1PR5 (0.91) | S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530462-B2 | Indole modulators of S1P receptors | ALLERGAN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530462-B2 | Indole modulators of S1P receptors | ALLERGAN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2012071184-A1 | INDOLE DERIVATIVES AS MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 4/4885P2RY12 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.